J&J Wins Ruling that Blocks Viatris’ Copies of Invega Trinza

Johnson & Johnson’s Janssen unit convinced a federal judge in New Jersey that Viatris Inc.’s proposed copy of Invega Trinza infringes a patent for the injectable schizophrenia treatment.

The label on Viatris subsidiary Mylan Laboratories Ltd.’s generic version will induce doctors and patients to infringe Janssen’s US Patent No. 10,143,693, according to an order issued Monday in the US District Court for the District of New Jersey.

Judge Evelyn Padin rejected Mylan’s argument that the patent, which expires in April 2036, shouldn’t have been issued. Padin also issued an opinion under seal and ordered the parties to jointly ...